Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.63 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.63 |
| ▸ | TTR | P02766 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | DHFR | P00374 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505879 | 0.87 | AKR1C3 (0.56) | AKR1C3AKR1C2TTRKDM4EMEN1 | |
| SCHEMBL475505 | 0.84 | TTR (0.57) | AKR1C3AKR1C2TTRKDM4EMEN1 | |
| SCHEMBL594843 | 0.84 | AKR1C3 (0.62) | AKR1C3AKR1C2LMNAKMOMAP2K4 | |
| SCHEMBL18397597 | 0.84 | AKR1C3 (0.64) | AKR1C3AKR1C2KMOFOLH1MAOA | |
| SCHEMBL411711 | 0.83 | MAOA (0.65) | AKR1C3AKR1C2TTRACMSDKMO | |
| SCHEMBL2562268 | 0.83 | AKR1C3 (0.63) | AKR1C3AKR1C2LMNAKMOFOLH1 | |
| SCHEMBL4346801 | 0.82 | KDM1A (0.53) | AKR1C3AKR1C2TTRKDM4EMEN1 | |
| SCHEMBL12663514 | 0.81 | AKR1C3 (0.51) | AKR1C3AKR1C2LMNAKMOMAP2K4 | |
| SCHEMBL30153181 | 0.81 | HDAC6 (0.77) | AKR1C3AKR1C2MEN1KMT2AMAP2K4 | |
| SCHEMBL12171515 | 0.81 | HDAC6 (0.62) | AKR1C3AKR1C2MAP2K4PTGER1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220184041-A1 | (AZA)Benzothiazolyl Substituted Pyrazole Compounds | PFIZER INC. (US) | 2022-06-16 | — | — | US | disclosed |
| WO-2022112919-A1 | (AZA)BENZOTHIAZOLYL SUBSTITUTED PYRAZOLE COMPOUNDS | PFIZER INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2020128816-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF A BENZOXAZOLE TRANSTHYRETIN STABILIZER AND AN ADDITIONAL THERAPEUTIC AGENT | PFIZER INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-2611774-B1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-18 | — | — | EP | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | disclosed |
| EP-2325651-B1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2421825-B9 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-20 | — | — | EP | disclosed |
| US-8759333-B2 | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | SYTERA, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| WO-2007008821-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | SIRION THERAPEUTICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20060135460-A1 | Methods, assays and compositions for treating retinol-related diseases | SYTERA, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006063128-A2 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INSTITUTE, THE | 2006-03-16 | — | — | US | disclosed |
| EP-1587821-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | The Scripps Research Institute (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040152140-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE | 2004-08-05 | — | — | US | disclosed |
| WO-2004056315-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | TTR, TTPA, PRNP | AKR1C3 2103/4885AKR1C2 2017/4885TTR 1/4885 |
| US-20060135460-A1 | Methods, assays and compositions for treating retinol-related diseases | RBP1, RBP4, TTR | AKR1C3 756/4885AKR1C2 1003/4885TTR 3/4885 |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | RBP1, RBP4, ALDH1A2 | AKR1C3 256/4885AKR1C2 507/4885TTR 25/4885 |
| US-20220184041-A1 | (AZA)Benzothiazolyl Substituted Pyrazole Compounds | TTR, APOB, SERPINB6 | AKR1C3 1540/4885AKR1C2 2882/4885TTR 1/4885 |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | TTR, TTPA, PRNP | AKR1C3 2213/4885AKR1C2 2437/4885TTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.